I say we retrace our losses from yesterday in short order. The Forbes article made the price for Gattex look
very reasonable. Orphan drugs are now the new thing for Bio's as the price makes up for the small
population of patients. Textbook buy and hold with upcoming pipeline, in place royalties and Gattex.